Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report

CytomX Therapeutics, Inc.‘s (NASDAQ:CTMX) share price was up 94.46% at last check on Monday. The stock surged after the company reported interim Phase 1 data for its EpCAM PROBODY ADC candidate, CX-2051, in advanced, late-line colorectal cancer (CRC). As of April 7, 25 advanced metastatic CRC…